• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

by Fred Pennic 05/20/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
White House, IBM Partner to Fight COVID-19 Using Supercomputers

What You Should Know: 

– The U.S. Department of Health and Human Services (HHS) announced it is taking immediate action to implement President Donald J. Trump’s Executive Order, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” 

– Under the leadership of President Trump, HHS Secretary Robert F. Kennedy Jr., and Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz, the Department has outlined specific targets for pharmaceutical manufacturers. 

– The administration anticipates highlighting these commitments in the coming weeks, with the goal of ensuring Americans no longer face higher medication costs than patients in economically comparable nations.

The Most-Favored-Nation Pricing Mandate

HHS expects pharmaceutical manufacturers to commit to aligning U.S. prices for all brand-name products that do not currently face generic or biosimilar competition with the lowest price found among a set of peer countries. The Most-Favored-Nation (MFN) target price is defined as the lowest price in an Organisation for Economic Co-operation and Development (OECD) country that has a GDP per capita of at least 60 percent of the U.S. GDP per capita.

Expected Impact: Lower Costs While Aiming to Preserve Innovation

Officials state that these targets are designed to drastically reduce U.S. drug prices, which are often reported to be three to five times higher than those abroad. The administration asserts that this policy will relieve an unfair financial burden on Americans while preserving innovation, by ensuring U.S. patients do not bear a greater cost for the same drugs than patients in other developed nations. 

The administration frames the move as a necessary step to correct an unfair burden on U.S. consumers. “For too long, Americans have been forced to pay exorbitant prices for the same drugs that are sold overseas for far less,” said Secretary Kennedy. “That ends today. We expect pharmaceutical manufacturers to fulfill their commitment to lower prices for American patients, or we will take action to ensure they do.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Redesign Health Study: 71% of Health Systems Adopt an "Epic-First" AI Purchasing Strategy

Redesign Health Study: 71% of Health Systems Adopt an “Epic-First” AI Purchasing Strategy

iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform

M&A: iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform

CB Insights Q2 2026 State of Digital Health Report: Fewest Deals in Over a Decade as Median Sizes Rise

CB Insights Q2 2026 State of Digital Health Report: Fewest Deals in Over a Decade as Median Sizes Rise

mount-sinai-launches-epic-chart-with-art-nursing-ambient-ai

Mount Sinai Medical Center Extends Epic’s Ambient AI to Inpatient Nursing

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

Why Brain Health Is Entering Its Infrastructure Era

Brain Health’s Infrastructure Era: Proving Clinical Outcomes with Integrated Neuromotor Tracking

Why Catholic Health Inked a $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

Catholic Health Inks $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |